

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, Mail Stop DD, PO Box 1450,
Alexandria, VA 22313 on March 25, 2004.



INFORMATION DISCLOSURE
STATEMENT
Patent Application
Docket No. ARYX-101XCD2
Serial No. 10/763,904

David Saliwanchik
David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Pascal Druzgala and Peter Milner
Serial No. : 10/763,904
Filed : January 23, 2004
For : Ultrashort Acting Hypnotic Barbiturates

Commissioner for Patents
Mail Stop DD
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.97 and §1.98(d), the applicants would like to bring to the attention of the Examiner, the references cited in the following patent applications:


U.S. Serial No. 10/145,601, filed May 13, 2002, now U.S. Patent No. 6,683,086.

U.S. Serial No. 09/841,738, filed April 24, 2001, now U.S. Patent No. 6,387,914.

The subject application, Serial No. 10/763,904 claims the benefit under 35 USC §120 of the filing date of the above applications. The applicants respectfully request that the copies of references supplied in the Information Disclosure Statements of the above-mentioned applications, as well as the references cited during prosecution thereof, be made of record in the 10/763,904 application. As copies of all of the references filed in the parent application, and cited on the attached form PTO/SB/08, will be found in the parent casenote, copies of those references are not provided herewith.

The applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, Florida 32606-6669

DRS/ue

Attachment: Form PTO/SB/08



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	1	of	2	Application Number	10/763,904
				Filing Date	January 23, 2004
				First Named Inventor	Pascal Druzgala
				Art Unit	not yet assigned
				Examiner Name	not yet assigned
				Attorney Docket Number	ARYX-101XCD2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-4,634,707 A	01-06-1987	Brewer	All
	U2	US-6,387,914 B2	05-14-2002	Druzgala et al.	All
	U3	US-6,683,086 B2	01-27-2004	Druzhala et al.	All
	U4	US-			
	U5	US-			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)			
	F1	CH 678394 A5	09-13-1992	Cerny, E.	All
	F2	WO 98/58925	12-30-1998	Boehringer	All
	F3	WO 93/20064	10-14-1993	Biosite Diagnostics	All
	F4	WO 91/08191	06-13-1991	Sloan-Kettering Inst.	All
	F5	FR 2 300 568 A	09-10-1976	SFOFA	All
	F6	DE 24 05 732 A	08-21-1975	Bayer	All
	F7				
	F8				
	F9				

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	2	of	2	Application Number	10/763,904
				Filing Date	January 23, 2004
				First Named Inventor	Pascal Druzgala
				Group Art Unit	not yet assigned
				Examiner Name	not yet assigned
				Attorney Docket Number	ARYX-101XCD2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	R1	Chemical Abstracts, Vol. 95, no. 7, 1981, page 42, Columbus, Ohio, US; abstract no. 54821y.		..
	R2	Chemical Abstracts, Vol. 97, no. 1, 1982, page 13, Columbus, Ohio, US; abstract no. 16559c.		
	R3	Chemical Abstracts, Vol. 100, no. 28, July 30, 1993, page 603, Columbus, Ohio, US; abstract no. 68316w.		
	R4	Chemical Abstracts, Vol. 126, no. 17, 1997, Columbus, Ohio, US; abstract no. 225269q, Abdel-Hamide , page 575		
	R5	MIREK, J. (1978) "Syunthesis A. Pharmacolgical Screening of Some N-Carboxymethylbarbituric Acid Derivatives 1" <i>Pol. J. Pharmacol.</i> 30:685-693.		
	R6	PORTER, R.J., MELDRUM, B.S. (1992) "Antiepileptic drugs" Basic & Clinical Pharmacology, Katzung B.G., Ed., Appleton & Lange, Norwalk, Conn., 5 th Edition, pp. 331-349.		
	R7	TREVOR, A.J., WAY, W.L. (1992) "Sedative-hypnotics" Basic & Clinical Pharmacology, Katzung B.G., Ed., Appleton & Lange, Norwalk, Conn., 5 th Edition, pp. 306-319.		
	R8			
	R9			
	R10			
	R11			
	R12			
	R13			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.